Answers are grounded in this paper and cite their sources.
Retrospective observational study shows effectiveness and long-term value of pembrolizumab in NSCLC, indicating important cost considerations.
Anti–PD-1/PD-L1 therapy has reshaped the therapeutic paradigm of metastatic NSCLC, improving survival and enabling durable benefit. However, the high upfront expenditure associated with immunotherapy has increased the need to frame real-world effectiveness within long-term value metrics, including quality-adjusted life-years (QALYs), disability-adjusted life-years (DALYs) and incremental cost-effectiveness ratios (ICERs), to better capture downstream gains in quality and quantity of life.
No takes yet. Share an insight, caveat, or question.
Ungaro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: